WO2007007095A3 - Pharmaceutical compositions comprising a tgf-beta superfamily member - Google Patents

Pharmaceutical compositions comprising a tgf-beta superfamily member Download PDF

Info

Publication number
WO2007007095A3
WO2007007095A3 PCT/GB2006/002574 GB2006002574W WO2007007095A3 WO 2007007095 A3 WO2007007095 A3 WO 2007007095A3 GB 2006002574 W GB2006002574 W GB 2006002574W WO 2007007095 A3 WO2007007095 A3 WO 2007007095A3
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
pharmaceutical compositions
superfamily member
beta superfamily
sugars
Prior art date
Application number
PCT/GB2006/002574
Other languages
French (fr)
Other versions
WO2007007095A2 (en
Inventor
Mark Ferguson
Sharon O'kane
Hugh Laverty
Nick Occleston
Jane Kelly
Wayne Burrill
Original Assignee
Renovo Ltd
Mark Ferguson
Sharon O'kane
Hugh Laverty
Nick Occleston
Jane Kelly
Wayne Burrill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0514259A external-priority patent/GB0514259D0/en
Priority claimed from GB0514260A external-priority patent/GB0514260D0/en
Application filed by Renovo Ltd, Mark Ferguson, Sharon O'kane, Hugh Laverty, Nick Occleston, Jane Kelly, Wayne Burrill filed Critical Renovo Ltd
Priority to CA002614754A priority Critical patent/CA2614754A1/en
Priority to JP2008520947A priority patent/JP2009501200A/en
Priority to BRPI0613731-8A priority patent/BRPI0613731A2/en
Priority to EP06764930A priority patent/EP1915169A2/en
Priority to AU2006268088A priority patent/AU2006268088B2/en
Priority to US11/995,399 priority patent/US7691816B2/en
Publication of WO2007007095A2 publication Critical patent/WO2007007095A2/en
Publication of WO2007007095A3 publication Critical patent/WO2007007095A3/en
Priority to IL188352A priority patent/IL188352A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)

Abstract

The invention provides pharmaceutical compositions comprising TGF-β superfamily members and sugars, the compositions allowing improved recovery and/or increased biological activity of the TGF- β superfamily member incorporated therein. The invention also relates to uses of sugars to improve the recovery or increase the biological activity of TGF-β superfamily members in a pharmaceutical composition. Uses of the pharmaceutical compositions are also described, particularly with reference to wound healing and fibrosis. Furthermore, the invention discloses medicaments for the prevention or reduction of injection pain.
PCT/GB2006/002574 2005-07-12 2006-07-12 Pharmaceutical compositions comprising a tgf-beta superfamily member WO2007007095A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002614754A CA2614754A1 (en) 2005-07-12 2006-07-12 Pharmaceutical compositions comprising a tgf-beta superfamily member
JP2008520947A JP2009501200A (en) 2005-07-12 2006-07-12 Pharmaceutical composition containing a TGF-β superfamily member
BRPI0613731-8A BRPI0613731A2 (en) 2005-07-12 2006-07-12 pharmaceutical composition, pre-filled container, as well as use of a sugar to enhance recovery and / or increase the biological activity of a tgf-beta superfamily member
EP06764930A EP1915169A2 (en) 2005-07-12 2006-07-12 Pharmaceutical compositions comprising a tgf-beta superfamily member
AU2006268088A AU2006268088B2 (en) 2005-07-12 2006-07-12 Pharmaceutical compositions comprising a TGF-beta superfamily member
US11/995,399 US7691816B2 (en) 2005-07-12 2006-07-12 Pharmaceutical compositions
IL188352A IL188352A0 (en) 2005-07-12 2007-12-24 Pharmaceutical compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0514260.9 2005-07-12
GB0514259A GB0514259D0 (en) 2005-07-12 2005-07-12 Pharmaceutical compositions
GB0514259.1 2005-07-12
GB0514260A GB0514260D0 (en) 2005-07-12 2005-07-12 Medicaments

Publications (2)

Publication Number Publication Date
WO2007007095A2 WO2007007095A2 (en) 2007-01-18
WO2007007095A3 true WO2007007095A3 (en) 2007-08-02

Family

ID=36971625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/002574 WO2007007095A2 (en) 2005-07-12 2006-07-12 Pharmaceutical compositions comprising a tgf-beta superfamily member

Country Status (9)

Country Link
US (1) US7691816B2 (en)
EP (1) EP1915169A2 (en)
JP (1) JP2009501200A (en)
KR (1) KR20080031394A (en)
AU (1) AU2006268088B2 (en)
BR (1) BRPI0613731A2 (en)
CA (1) CA2614754A1 (en)
IL (1) IL188352A0 (en)
WO (1) WO2007007095A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514262D0 (en) * 2005-07-12 2005-08-17 Renovo Ltd Promotion of epithelial regeneration
GB0604938D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Proteins, nucleic acids and medicaments
GB0604966D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Medicaments and proteins
GB0604964D0 (en) * 2006-03-11 2006-04-19 Renovo Ltd Protein folding
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
GB0724203D0 (en) * 2007-12-12 2008-01-23 Renovo Ltd Methods for the inhibition of scarring
GB0821941D0 (en) 2008-12-01 2009-01-07 Renovo Ltd Non-surgical improvements of scars
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
FR2940608B1 (en) * 2008-12-30 2011-04-22 Oreal USE OF MONOSACCHARIDES AND COMPOSITION
KR101177375B1 (en) * 2010-02-19 2012-08-27 강원대학교산학협력단 Pharmaceutical compositions for wound healing comprising MIC-1 gene or protein
EP2590667A4 (en) * 2010-07-07 2013-11-27 Biodel Inc Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
CA2880653C (en) * 2012-08-01 2022-05-17 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
WO2016118866A1 (en) * 2015-01-23 2016-07-28 Puretein Bioscience Llc Methods for treating inflammation with tgf-beta
WO2017025965A1 (en) 2015-08-13 2017-02-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
TWI705820B (en) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1 agonist compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010758A1 (en) * 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
WO1998004681A2 (en) * 1996-07-25 1998-02-05 Genzyme Corporation Chondrocyte media formulations and culture procedures
WO2001048147A1 (en) * 1999-12-28 2001-07-05 Iso Tis N.V. Cell culture medium containing growth factors and l-glutamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7341994B2 (en) * 2000-04-25 2008-03-11 Otsuka Pharmaceutical Co., Ltd. GD3-mimetic peptides
AU2002236587A1 (en) * 2000-11-21 2002-06-03 Michael P. Diamond Compositions for adhesion prevention
US8946295B2 (en) * 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
JP2006508127A (en) * 2002-11-06 2006-03-09 アルザ・コーポレーション Controlled release depot formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010758A1 (en) * 1991-12-05 1993-06-10 Pitman-Moore, Inc. A carbohydrate glass matrix for the sustained release of a therapeutic agent
WO1998004681A2 (en) * 1996-07-25 1998-02-05 Genzyme Corporation Chondrocyte media formulations and culture procedures
WO2001048147A1 (en) * 1999-12-28 2001-07-05 Iso Tis N.V. Cell culture medium containing growth factors and l-glutamine

Also Published As

Publication number Publication date
CA2614754A1 (en) 2007-01-18
BRPI0613731A2 (en) 2011-02-01
AU2006268088B2 (en) 2011-05-12
JP2009501200A (en) 2009-01-15
US7691816B2 (en) 2010-04-06
US20080176799A1 (en) 2008-07-24
AU2006268088A1 (en) 2007-01-18
IL188352A0 (en) 2008-04-13
KR20080031394A (en) 2008-04-08
EP1915169A2 (en) 2008-04-30
WO2007007095A2 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2007007095A3 (en) Pharmaceutical compositions comprising a tgf-beta superfamily member
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006055672A3 (en) Methods and compositions for treating pain
EP2269631A3 (en) Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009120365A3 (en) Methods and compositions for the delivery of agents
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2007128817A3 (en) Insulin derivative
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007129270A3 (en) Cosmetic compositions comprising at least one peptide with at least one immobilized aromatic cycle
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
WO2007102686A8 (en) Peptides having activities of insulin like growth factor-1 and their uses
WO2009040420A3 (en) Use of a monoterpene to increase tissue repair
WO2007005941A3 (en) Liver targeted conjugates
WO2007144493A3 (en) Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
EP2540301A3 (en) Methods and pharmaceutical compositions for healing wounds
IL189270A (en) Phosphonated rifamycins and derivatives thereof, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for the prevention and treatment of bone and joint infections
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2009059755A3 (en) Novel neurturin conjugates for pharmaceutical use
PL1893237T3 (en) Pharmaceutical composition comprising an organopolysiloxane elastomer and a solubilized active principle
WO2006083927A3 (en) Antimicrobial agent

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 564906

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 188352

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 156/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008010030

Country of ref document: EG

Ref document number: 2614754

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006268088

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12008500089

Country of ref document: PH

Ref document number: MX/A/2008/000661

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008520947

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 08008623

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2006268088

Country of ref document: AU

Date of ref document: 20060712

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006268088

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006764930

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087003287

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11995399

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 200680033479.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06764930

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006764930

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0613731

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080114